

UHC COVID-19 Treatment Claims

Below is an update for you regarding the extension of the National Emergency.

The U.S. Department of Health and Human Services (HHS) has renewed the public health emergency for an additional 90 days through April 20. As a result, the following will be extended through April 20:

- UnitedHealthcare will cover medically appropriate COVID-19 testing and test-related visits for fully insured and self-funded (ASO) customers in- and out-of-network **during the national public health emergency, now extended through April 20**. Testing must be ordered by a physician or appropriately licensed health care professional for purposes of the diagnosis or treatment of an individual member.
 - UnitedHealthcare will only cover testing for employment, education, public health or surveillance purposes when required by applicable law. Benefits will be adjudicated in accordance with a member's benefit plan; **health benefit plans generally do not cover testing for surveillance or public health purposes**.

COVID-19 treatment extensions to Jan. 31

Applies to fully insured and ASO customers that follow UnitedHealthcare standard coverage

- UnitedHealthcare is extending the cost-share waiver for inpatient treatment through Jan. 31 for a member with a COVID-19 diagnosis who is admitted as an inpatient to a network hospital.
- The emergency room would be covered at no cost-share through Jan. 31 if the patient is admitted to the network facility with a COVID-19 diagnosis.
- Cost-share will be waived through Jan. 31 for medically necessary ground transportation if the result is an admission to the facility.

COVID-19 monoclonal antibodies outpatient treatment

- Monoclonal antibodies for COVID-19 monoclonal antibodies COVID-19 outpatient treatment (bamlanivimab, casirivimab and imdevimab) are covered as an outpatient treatment at plan benefits through the April 20 public health emergency.
- **Important:** UnitedHealthcare has waived cost-share for monoclonal antibody treatment in-network through Jan. 31. The government supplies the monoclonal antibody product, and UnitedHealthcare – or self-funded (ASO) customers that follow UnitedHealthcare standard benefits – will waive cost-share for the administration of the monoclonal antibodies only.